VP: Lundbeck first with new Alzheimer’s drug
New requirements from the FDA increases the probability of an approval of Lundbeck’s new candidate drug to treat Alzheimer’s as the next on the market. But rivals are waiting in the stands – especially drug giant Eli Lilly.
by Benjamin Werner Christensen
In spite of intense global competition, Lundbeck has a chance of becoming the first drug company in the world to launch a new drug to treat Alzheimer’s disease.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Doctors represent hurdle for Lundbeck once again
For abonnenter
Here are Lundbeck’s best-performing drugs
For abonnenter
Lundbeck launches alcohol pill in Denmark
For abonnenter
